Journal of Stroke & Cerebrovascular Diseases
Volume 17, Issue 3 , Pages 129-133 , May 2008

Type 3 Phosphodiesterase Inhibitors May Be Protective Against Cerebrovascular Events in Patients with Claudication

  • William M. Stone, MD

      Affiliations

    • Division of Vascular Surgery, Mayo Clinic College of Medicine. Mayo Clinic Arizona, Phoenix, Arizona
    • Corresponding Author InformationAddress correspondence to William M. Stone, MD, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85054.
    • ,
  • Bart M. Demaerschalk, MD, MSc, FRCP(C)

      Affiliations

    • Department of Neurology, Mayo Clinic College of Medicine. Mayo Clinic Arizona, Phoenix, Arizona
    • ,
  • Richard J. Fowl, MD

      Affiliations

    • Division of Vascular Surgery, Mayo Clinic College of Medicine. Mayo Clinic Arizona, Phoenix, Arizona
    • ,
  • Samuel R. Money, MD, MBA

      Affiliations

    • Division of Vascular Surgery, Mayo Clinic College of Medicine. Mayo Clinic Arizona, Phoenix, Arizona

Received 13 August 2007 ,Revised 8 December 2007 ,Accepted 19 December 2007.

References 

  1. Newman AB, Siscovick DS, Manolio TA, et al. Atherosclerosis: Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Circulation. 1993;88:837–845
  2. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–1339
  3. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US preventive services task force. Ann Intern Med. 2000;136:161–172
  4. Halkes P, van Gijn J, Kappelle L, et al. Aspirin plus dipyridamole vs. aspirin alone after cerebral ischemia of arterial origin (ESPRIT): Randomized controlled trial. Lancet. 2006;367:1665–1673
  5. Bhatt D, Fox K, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717
  6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  7. Kambayashi J, Liu Y, Sun B, et al. Cilostazol as a unique antithrombotic agent. Curr Pharm Des. 2003;9:2289–2302
  8. Packer M. Cardiovascular and Renal Drugs Advisory Committee, 85th Meeting, July 9, 1998. Bethesda, MD: Food and Drug Administration, U.S. Department of Health and Human Services.
  9. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147–157
  10. Hiatt WM, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: a study in long-term effects). J Vasc Surg. 2008;47:330–336
  11. Goldstein LB, Adams R, Alberts MJ, et al. Guidelines for prevention of stroke in patients with ischemic strokes or transient ischemic attacks: A statement for healthcare professionals from the American Heart Association/American Stroke Association council on stroke; co-sponsored by the council on cardiovascular radiology and intervention, the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577–617
  12. Storey RF, Sanderson HM, White AE, et al. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925–934
  13. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood. 1998;92:3240–3249
  14. Aktas B, Utz A, Hoenig-Liedl P, et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: In vitro and in vivo/ex vivo studies. Stroke. 2003;34:764–769
  15. Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985;35:1144–1149
  16. Horiuchi M, Sugihara H, Koboyashi H, et al. Effect of cilostazol on carotid blood and cutaneous microcirculation flows. Diagn Treat. 1996;84:523–530
  17. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942–1947
  18. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36:782–786
  19. Take S, Matsutani M, Ueda H, et al. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1997;79:1097–1099

PII: S1052-3057(08)00010-4

doi: 10.1016/j.jstrokecerebrovasdis.2007.12.005

Journal of Stroke & Cerebrovascular Diseases
Volume 17, Issue 3 , Pages 129-133 , May 2008

Article Tools